Zydus Lifesciences receives tentative FDA approval for Letermovir tablets
In a significant development for patients undergoing bone marrow or kidney transplants, Zydus Lifesciences Limited has been granted tentative approval by the United States Food and Drug Administration (USFDA) for its Letermovir tablets in 240 mg and 480 mg formulations. This approval marks a crucial step in preventing disease caused by cytomegalovirus (CMV) in these […]